. France, P. Morlat, Prise en charge médicale des personnes vivant avec le VIH Rapport 2013: recommandations du groupe d'experts, DILA -Direction de l'information légale et administrative : La documentation française, Ministère des affaires sociales et de la santé, 2012.
URL : https://hal.archives-ouvertes.fr/in2p3-00019242

L. Mandelbrot, R. Tubiana, J. L. Chenadec, C. Dollfus, A. Faye et al.,

M. Matheron, V. Khuong, V. Garrait, A. Reliquet, A. Devidas et al., No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.61, pp.1715-1725, 2015.

L. M. Mofenson, In-utero ART exposure and the need for pharmacovigilance, Lancet Glob. Health, vol.6, issue.18, pp.30272-30281, 2018.

M. I. Murray, M. Markowitz, I. Frank, R. M. Grant, K. H. Mayer et al.,

S. L. Stancil, P. Ford, A. R. Patel, W. R. Rinehart, D. A. Spreen et al., Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial, HIV Clin. Trials, vol.19, pp.129-138, 2018.

D. A. Margolis, J. Gonzalez-garcia, H. Stellbrink, J. J. Eron, Y. Yazdanpanah et al.,

M. Clair, S. L. Murray, J. Ford, P. Mrus, H. Patel et al., Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, openlabel, phase 2b, non-inferiority trial, Lancet Lond. Engl, vol.390, pp.31917-31924, 2017.

D. A. Margolis, C. C. Brinson, G. H. Smith, J. Vente, D. P. Hagins et al.,

M. H. Griffith, M. C. Clair, P. E. Stevens, S. L. Williams, B. S. Ford et al., LAI116482 Study Team, Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial, Lancet Infect. Dis, vol.15, pp.152-160, 2015.

P. E. Sax, A. Pozniak, M. L. Montes, E. Koenig, E. Dejesus et al.,

K. Antinori, J. Workowski, J. Slim, W. Reynes, J. Garner et al., Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. inferiority trial, Lancet Lond. Engl, vol.390, issue.17, pp.32340-32341, 2017.

R. Van-der-galiën, R. Heine, R. Greupink, S. J. Schalkwijk, A. E. Van-herwaarden et al., Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps, vol.58, pp.309-323, 2019.

R. Zash, L. Holmes, M. Diseko, D. L. Jacobson, S. Brummel et al., Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana, N. Engl. J. Med, vol.381, pp.827-840, 2019.

. Statement_on_dtg_18may_2018final and . Pdf,

V. Vannappagari, C. Thorne, and . Eppicc, Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir, J. Acquir. Immune Defic. Syndr, vol.81, pp.371-378, 1999.

J. Reefhuis, L. F. Fitzharris, K. M. Gray, S. Nesheim, S. C. Tinker et al.,

J. Laffoon, K. Lowry, J. D. Poschman, F. K. Cragan, J. E. Stephens et al., Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection -15 Jurisdictions, vol.69, pp.1-5, 2013.

L. Gavard, D. Beghin, F. Forestier, Y. Cayre, G. Peytavin et al., Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs, Eur. J. Obstet. Gynecol. Reprod. Biol, vol.147, pp.157-160, 2009.

P. Ceccaldi, C. Ferreira, L. Gavard, S. Gil, G. Peytavin et al., Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model, Am. J. Obstet. Gynecol, vol.198, pp.433-434, 2008.

P. Bapat, L. S. Pinto, A. Lubetsky, H. Berger, and G. Koren, Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am. J. Obstet. Gynecol, vol.213, pp.1-6, 2015.

M. Mendes, G. Lui, Y. Zheng, C. Pressiat, D. Hirt et al., A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways, Clin. Pharmacokinet, vol.56, pp.537-550, 2017.

J. A. Smith, A. Gaikwad, S. Mosley, L. Coffer, J. Cegelski et al., Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy, Am. J. Obstet. Gynecol, vol.210, p.1, 2014.


W. Spreen, S. Min, S. L. Ford, S. Chen, Y. Lou et al., Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor, HIV Clin. Trials, vol.14, pp.192-203, 2013.

V. Faure-bardon, L. Mandelbrot, D. Duro, C. Dussaux, M. Le et al., Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model, AIDS Lond. Engl, vol.32, pp.321-325, 2018.

L. Gavard, S. Gil, G. Peytavin, P. Ceccaldi, C. Ferreira et al., Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model, Am. J. Obstet. Gynecol, vol.195, pp.296-301, 2006.

P. Ceccaldi, L. Gavard, L. Mandelbrot, E. Rey, R. Farinotti et al., Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model, Obstet. Gynecol. Int, 2009.

L. Mandelbrot, D. Duro, E. Belissa, and G. Peytavin, Placental transfer of darunavir in an ex vivo human cotyledon perfusion model, Antimicrob. Agents Chemother, vol.58, pp.5617-5620, 2014.

J. C. Challier, P. D'athis, M. Guerre-millo, and M. Nandakumaran, Flow-dependent transfer of antipyrine in the human placenta in vitro, Reprod. Nutr. Dev, vol.23, pp.41-50, 1983.
URL : https://hal.archives-ouvertes.fr/hal-00898027

H. Schneider, M. Panigel, and J. Dancis, Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am. J. Obstet. Gynecol, vol.114, pp.822-828, 1972.

C. Vinot, L. Gavard, J. M. Tréluyer, S. Manceau, E. Courbon et al., Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression, Antimicrob. Agents Chemother, vol.57, pp.1415-1420, 2013.

L. Mandelbrot, D. Duro, E. Belissa, and G. Peytavin, Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model, Antimicrob. Agents Chemother, vol.59, pp.2901-2903, 2015.

©. Copyright, Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited, 2020.

B. H. Jung, N. L. Rezk, A. S. Bridges, A. H. Corbett, and A. D. Kashuba, Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry, Biomed. Chromatogr. BMC, vol.21, pp.1095-1104, 2007.

G. Iacobucci, HIV: dolutegravir should be preferred treatment option in all populations, says WHO, BMJ, vol.366, 2019.

J. B. Pain, M. P. Lê, M. Caseris, C. Amiel, L. Lassel et al., Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy, Antimicrob. Agents Chemother, vol.59, pp.3660-3662, 2015.

C. Waitt, C. Orrell, S. Walimbwa, Y. Singh, K. Kintu et al., Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study), PLoS Med, vol.16, 2019.

L. Mandelbrot, P. Ceccaldi, D. Duro, M. Lê, L. Pencolé et al., Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model, PloS One, vol.14, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02272841

S. Schalkwijk, R. Greupink, A. P. Colbers, A. C. Wouterse, V. G. Verweij et al., Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model, J. Antimicrob. Chemother, vol.71, pp.480-483, 2016.

D. Pubchem,

C. Pubchem,

C. Vinot, J. Tréluyer, C. Giraud, L. Gavard, G. Peytavin et al., Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob. Agents Chemother, vol.60, pp.3112-3114, 2016.

G. D. Bowers, A. Culp, M. J. Reese, G. Tabolt, L. Moss et al., Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans, Xenobiotica Fate Foreign Compd. Biol. Syst, vol.46, pp.147-162, 2016.

T. S. Tracy, R. Venkataramanan, D. D. Glover, and S. N. Caritis, National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units, Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy, Am. J. Obstet. Gynecol, vol.192, pp.633-639, 2005.

©. Copyright, Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited, 2020.

A. Dallmann, X. I. Liu, G. J. Burckart, J. Van-den, and . Anker, Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal-Fetal Drug Transfer, J. Clin. Pharmacol, vol.59, issue.1, pp.70-81, 2019.

A. T. Podany, K. K. Scarsi, and C. V. Fletcher, Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors, Clin. Pharmacokinet, vol.56, pp.25-40, 2017.

M. E. Clement, R. Kofron, and R. J. Landovitz, Long-acting injectable cabotegravir for the prevention of HIV infection, Curr. Opin. HIV AIDS, vol.15, pp.19-26, 2020.

M. Mendes, D. Hirt, C. Vinot, E. Valade, G. Lui et al., Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models, Br. J. Clin. Pharmacol, vol.81, pp.646-657, 2016.

V. Karttunen, H. Sahlman, J. K. Repo, C. S. Woo, K. Myöhänen et al., Criteria and challenges of the human placental perfusion -Data from a large series of perfusions, Toxicol. Vitro Int. J. Publ. Assoc. BIBRA, vol.29, pp.1482-1491, 2015.

J. R. Hutson, F. Garcia-bournissen, A. Davis, and G. Koren, The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs, Clin. Pharmacol. Ther, vol.90, pp.67-76, 2011.